ERBB2 and breast carcinoma: Davey et al. carried out a systematic review highlighting the ability of miRNAs to be used as biomarkers predictive of the response of early stage HER-2-overexpressing breast cancers to neoadjuvant chemotherapy and/or anti-HER-2 therapies, with 41 miRNAs showing increased expression in patients who responded to neoadjuvant therapy, and 29 miRNAs with reduced expression in patients who responded [62].